Education
About Us
Working with TipRanks
Follow Us
OS Therapies Incorporated (OSTX)
:OSTX
OSTX Stock Chart & Stats
$1.83
$0.51(10.41%)
At close: 4:00 PM EST
$1.83
$0.51(10.41%)
Day’s Range― - ―
52-Week Range$1.12 - $7.00
Previous CloseN/A
Volume28.07K
Average Volume (3M)382.04K
Market Cap
$62.71M
Enterprise Value$46.22M
Total Cash (Recent Filing)$2.80M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.27
Next Earnings
Nov 14, 2025EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding33,532,490
10 Day Avg. Volume310,151
30 Day Avg. Volume382,036
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.74
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-403.34
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$12.00Price Target Upside555.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Clinical Trial Success75% of OST-HER2 treated patients achieved 2-year overall survival compared to 40% for historical control.
Market OpportunityThe efficacy data was viewed as encouraging, with a significant statistical difference in overall survival compared to historical controls.
Regulatory SupportOST-HER2 holds FDA Orphan, Fast Track, and Rare Pediatric Disease designations, making it eligible for a priority review voucher if approved.
Bears Say
OS Therapies Incorporated News
OSTX FAQ
What was OS Therapies Incorporated’s price range in the past 12 months?
OS Therapies Incorporated lowest stock price was $1.12 and its highest was $7.00 in the past 12 months.
What is OS Therapies Incorporated’s market cap?
OS Therapies Incorporated’s market cap is $62.71M.
When is OS Therapies Incorporated’s upcoming earnings report date?
OS Therapies Incorporated’s upcoming earnings report date is Nov 14, 2025 which is in 9 days.
How were OS Therapies Incorporated’s earnings last quarter?
OS Therapies Incorporated released its earnings results on Aug 19, 2025. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of -$0.115 by -$0.075.
Is OS Therapies Incorporated overvalued?
According to Wall Street analysts OS Therapies Incorporated’s price is currently Undervalued.
Does OS Therapies Incorporated pay dividends?
OS Therapies Incorporated does not currently pay dividends.
What is OS Therapies Incorporated’s EPS estimate?
OS Therapies Incorporated’s EPS estimate is -0.12.
How many shares outstanding does OS Therapies Incorporated have?
OS Therapies Incorporated has 33,532,490 shares outstanding.
What happened to OS Therapies Incorporated’s price movement after its last earnings report?
OS Therapies Incorporated reported an EPS of -$0.19 in its last earnings report, missing expectations of -$0.115. Following the earnings report the stock price went down -1.376%.
Which hedge fund is a major shareholder of OS Therapies Incorporated?
Currently, no hedge funds are holding shares in OSTX
OS Therapies Incorporated Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.00 (555.74% Upside)
$12.00 (555.74% Upside)
Blogger Sentiment
Bullish
OSTX Sentiment 70%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 1.4%
Last 30 Days ▼ 1.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-28.89%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
668.17%
Trailing 12-Months
Company Description
OS Therapies Incorporated
OS Therapies Incorporated (OSTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of cancer and other serious diseases. The company operates within the healthcare sector, with a strong emphasis on oncology research and development. Its core products and services include the creation of targeted therapies designed to improve patient outcomes and quality of life through advanced scientific approaches.
OSTX Stock 12 Month Forecast
Average Price Target
$12.00
▲(555.74% Upside)
Technical Analysis
Actinium Pharmaceuticals
―
Adverum Biotechnologies
―
Annovis Bio
―
Gain Therapeutics
―
Klotho Neurosciences
―
Ownership Overview
15.63% Insiders
0.07% Mutual Funds
0.04% Other Institutional Investors
83.91% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---